Loading...

Anti-platelet therapy: glycoprotein IIb-IIIa antagonists

Glycoprotein (GP) IIb-IIIa antagonists inhibit the aggregation of activated platelets. Three agents are approved for clinical use. In this review, the characteristics of each agent, their pharmacodynamic profile, results in pivotal clinical trials and the associated clinical implications are discuss...

Full description

Saved in:
Bibliographic Details
Main Author: Schneider, David J
Format: Artigo
Language:Inglês
Published: Blackwell Science Inc 2011
Subjects:
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3195742/
https://ncbi.nlm.nih.gov/pubmed/21906121
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2010.03879.x
Tags: Add Tag
No Tags, Be the first to tag this record!